nach oben

Erschienen in:

01.09.2011 | Original Article

Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)

verfasst von: Eun Yoon Cho, Myung Hee Chang, Yoon La Choi, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancer (TNBC) exhibits a distinct pattern of recurrence characterized by a rapidly rising rate in the first 2 years with a peak at 2–3 years, followed by a decline over the next 5 years. However, some TNBC patients exhibit indolent clinical behavior. The aim of this study was to investigate clinical characteristics and outcomes of metastatic TNBCs. In addition, we were to find out the marker which could divide TNBCs into a few subgroups according to different clinical features.

Methods

We retrospectively analyzed the clinicopathologic characteristics and outcomes of patients with metastatic TNBC who received palliative treatment between 1999 and 2007.

Results

The median relapse-free survival (RFS) and overall survival (OS) of 152 patients were 24 and 20 months, respectively. Divided TNBCs based on a RFS of 36 months, the patients with a RFS of ≥36 months had a better disease control rate (DCR), progression-free survival (PFS), and OS than those with a RFS of <3 years. Cox-regression multivariate analysis for RFS and OS revealed EGFR positivity and a low BRCA1 score as an independent risk factor for OS.

Conclusions

The patients with a RFS ≥ 3 years had a significantly better DCR, PFS, and OS than patients who had a RFS < 3 years. BRCA1 and EGFR expression may be candidate determinants to distinguish RFS. A prospective clinical trial for different therapeutic strategies is needed for each subgroup.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale Al, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO (2009) Triple negative breast cancer: distinguishing basal and nonbasal subtypes. Clin Cancer Res 15:2302–2310PubMedCrossRef

Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancer: clinical and prognostic implications. Eur J Cancer Suppl 1:27–40

Linn SC, Vant’t Veer LJ (2009) Clinical relevance of triple negative breast cancer concept. Eur J Cancer 45(Suppl 1):11–26PubMedCrossRef

Viale G, Bottiglieri L (2009) Pathologic definition of triple negative breast cancer. Eur J Cancer 45(Suppl 1):5–10PubMedCrossRef

Yamamoto Y, Ibusuki M, Nakano M (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260–267PubMedCrossRef

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM (2009) Coordinated expression of ER, PR, and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 55:346–352PubMedCrossRef

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37:1217–1226PubMedCrossRef

Cleator S, Heller W, Coombes RC (2009) Triple-negative breast cancer: therapeutic options. Lancet Oncol 8:235–244CrossRef

10.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH (2009) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124:1457–1462PubMedCrossRef

11.

Eichhorn JH (2004) Medullary carcinoma, provocative now as then. Semin Diagn Pathol 21:65–73PubMedCrossRef

12.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281PubMedCrossRef

13.

Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657PubMedCrossRef

14.

Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO (2008) The influence of basal phenotype on the metastatic pattern of breast cancer. Clin Oncol (R Coll Radiol) 20:40–45

15.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef

16.

Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D, Reis-Filho JS, Ellis IO (2008) Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 99:327–334PubMedCrossRef

17.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef

18.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334PubMedCrossRef

19.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple negative breast cancer. Cancer 109:25–32PubMedCrossRef

20.

Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, MuCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and end results database. Cancer 110:876–884PubMedCrossRef

21.

Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010) Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 23:123–133PubMedCrossRef

22.

Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41:40–47PubMedCrossRef

23.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deminh SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

24.

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics subcommittee of NCI-EORTC working group on cancer diagnostics (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184PubMedCrossRef

25.

Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef

26.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115:423–428PubMedCrossRef

27.

Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134PubMedCrossRef

28.

Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kücücük S, Dincer M, Aydiner A, Topuz E (2008) MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 19:669–674PubMedCrossRef

29.

Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, Lebrecht A, Siggelkow W, Weikel W, Schiffer-Petry I, Gebhard S, Pilch H (2008) Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14:5849–5855PubMedCrossRef

30.

Turner N, Tutt A, Ashworth A (2004) Hallmark of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819PubMedCrossRef

31.

Diaz LK, Cryns VL, Symmans WF (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14:419–430PubMedCrossRef

32.

Jaspers JE, Rottenberg S, Jonkers J (2009) Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochimica Biophysica Acta 1796:266–280

33.

Chen JQ, Russo J (2009) ERα-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochimica Biophysica Acta 1796:162–175

34.

Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Medicine 15:907–915CrossRef

35.

Dizdar O, Dede DS, Bulut N, Altundag K (2008) Dasatinib may also inhibit c-Kit in triple negative breast cancer. Breast Cancer Res Treat 107:303PubMedCrossRef

36.

Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244PubMedCrossRef

37.

O’Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B, Bradley C (2009) Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitors in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27: 793s (abstract # 3)

38.

Carey LA, Rugo HS, Marcom PK, Irvin Jr W, Ferraro M, Burrows E, He X, Perou CM, Winer EP (2008) TBCRC 001. EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 26: 43s (abstract # 1009)

Titel: Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)
verfasst von: Eun Yoon Cho
Myung Hee Chang
Yoon La Choi
Jeong Eon Lee
Seok Jin Nam
Jung-Hyun Yang
Yeon Hee Park
Jin Seok Ahn
Young-Hyuck Im
Publikationsdatum: 01.09.2011
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1548-x

Springer Medizin

Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC)